about
Update of TTD: Therapeutic Target DatabaseCo-expression of anti-NFkappaB RNA aptamers and siRNAs leads to maximal suppression of NFkappaB activity in mammalian cells.Fishing for Nature's Hits: Establishment of the Zebrafish as a Model for Screening Antidiabetic Natural ProductsInhibition of microglia activation as a phenotypic assay in early drug discoveryDiscovery and characterization of olokizumabPubChem as a public resource for drug discoverySmall molecule modifier screen for kit-dependent functions in zebrafish embryonic melanocytesNetwork-based relating pharmacological and genomic spaces for drug target identificationProteins with complex architecture as potential targets for drug design: a case study of Mycobacterium tuberculosisThe Human Kinome Targeted by FDA Approved Multi-Target Drugs and Combination Products: A Comparative Study from the Drug-Target Interaction Network PerspectiveOpen access high throughput drug discovery in the public domain: a Mount Everest in the making.Removing obstacles in neuroscience drug discovery: the future path for animal models.Emerging Approaches to Tuberculosis Drug Development: At Home in the Metabolome.A novel framework for the identification of drug target proteins: Combining stacked auto-encoders with a biased support vector machineScreening phage display libraries for organ-specific vascular immunotargeting in vivoHigh-throughput screening and small animal models, where are we?A systems biology approach to identify effective cocktail drugs.A machine learning approach for genome-wide prediction of morbid and druggable human genes based on systems-level data.Screening for small molecule inhibitors of embryonic pathways: sometimes you gotta crack a few eggs.Genome-wide RNAi screen in IFN-γ-treated human macrophages identifies genes mediating resistance to the intracellular pathogen Francisella tularensis.A novel zebrafish human tumor xenograft model validated for anti-cancer drug screening.Anticancer drug development incorporating high-content screening and RNAi: synergistic approaches to improve target identification and validation.Functional interrogation of breast cancer: from models to drugs.Identification of drug targets in vitro and in living cells by soluble-nanopolymer-based proteomics.Structural modelling and comparative analysis of homologous, analogous and specific proteins from Trypanosoma cruzi versus Homo sapiens: putative drug targets for chagas' disease treatment.Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery.Antibody-based enrichment of peptides on magnetic beads for mass-spectrometry-based quantification of serum biomarkersNovel molecular diagnostic and therapeutic targets in chronic lymphocytic leukaemia.Pharmacogenetics and drug development: the path to safer and more effective drugs.Loss-of-function genetic diseases and the concept of pharmaceutical targets.Small zebrafish in a big chemical pond.The promise of genomics to identify novel therapeutic targets.A high-content screening platform with fluorescent chemical probes for the discovery of first-in-class therapeutics.Development of a vestibular schwannoma xenograft zebrafish model for in vivo antitumor drug screening.The target discovery process.In vivo chemical screening for modulators of hematopoiesis and hematological diseasesHow molecular profiling could revolutionize drug discovery.Application of GQSAR for Scaffold Hopping and Lead Optimization in Multitarget Inhibitors.Genomics and systems biology--how relevant are the developments to veterinary pharmacology, toxicology and therapeutics?Drug repurposing: far beyond new targets for old drugs.
P2860
Q24643206-FCE18F61-29FB-494E-9A6A-2008367256B5Q25255937-3EBFCE4E-BCB7-49FF-B932-2BEC3F801EB1Q26774936-A4830FD5-E006-48ED-B5B5-D0165FCD516BQ26996061-1817A9BD-5DC1-4ED4-846B-AA9115BC74C6Q27682535-DB6F1D54-3CBA-496C-B205-EAFA86C0D1B8Q28111749-E339BC09-7650-4E18-9217-705E7DBB6F3BQ28468692-75688B62-13BE-43A1-9E15-18AD6C559AD2Q28474912-1C35A2EE-1E2F-4150-804B-CB68B9B58016Q28479221-4CD74DB5-F7F4-4565-A9A9-F16304EFBF42Q28553277-8453B916-514C-4477-A279-E7A96986C9E8Q28677005-5BDF5CE6-1D13-4DDA-B9B2-6F8DAE976E06Q28755229-7416A7C1-11F7-45EF-8D54-37353F1F21A0Q30236042-DD2F694A-6C23-470A-8A80-2C4706254A37Q30356628-4066EB81-C515-4A64-B5CC-1F1493CFA89EQ33230544-2821E90E-50A0-4E80-B6C6-6274EA4FB5B5Q33566144-6A5C040B-345C-45D3-A4FF-AA145DB10653Q33692329-1F68E495-6155-4C0D-9839-20D46AF4D3CCQ33787296-02388294-667D-43CD-8A41-4136C846F0C2Q34133507-1B172887-2D2F-4B94-A329-6E54F836F707Q34168376-80EA6ACD-68A3-4350-B56F-9FD74257BBE8Q34262700-95EB39B2-E6E2-4723-9D55-EB81ED1C64E6Q34626275-DFCCA62C-B582-4F9B-99FA-B3CF2CBC18FDQ34626308-8BDCBEB9-C28C-41BB-A251-E13D0ECD2AA5Q34891724-2402635C-89E4-4D2A-88B6-DE62F3F627D7Q34968549-517D1EF5-76E8-44DB-90F9-ED8BAD939F81Q35631111-55FBC3ED-E022-4F24-83EE-C1D0E123F7C6Q35751680-ABFD9CEB-6201-4899-8ED0-D162388972F8Q35854960-8102AEDC-E820-4AEE-9103-EE94DA78D923Q35889605-85525EBF-DAD1-4EB1-89AF-A211308F9A06Q35919298-7294BBF9-F338-472C-BF95-2FA47B0093EAQ35951647-7ED1ADAF-143F-444A-94C2-4AAD2AD96B20Q35976369-88AAD623-99FE-40BC-BD2B-120975658783Q36013948-DD113154-96BF-472A-9CC6-B7B475D513B7Q36034475-8CADFD8A-7348-4546-A0EC-E995474599E5Q36059506-04A9E3AD-23FF-459D-B38F-2649E89F09F5Q36065342-45C478E2-A5D4-4982-A484-D2FD946D165DQ36079232-791BAEE4-3805-4474-B41D-E2694684ECB0Q36091289-2A265B4F-F6AA-4604-AD2C-3F17FFD9BF20Q36161532-8B8397C8-6F04-4736-B92A-6E22119C7CA7Q36331528-EFD7B197-79A5-4745-B451-04E7934A2CAC
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Target discovery.
@ast
Target discovery.
@en
Target discovery.
@nl
type
label
Target discovery.
@ast
Target discovery.
@en
Target discovery.
@nl
prefLabel
Target discovery.
@ast
Target discovery.
@en
Target discovery.
@nl
P356
P1476
Target discovery.
@en
P2093
Mark A Lindsay
P2888
P304
P356
10.1038/NRD1202
P577
2003-10-01T00:00:00Z